Verastem (VSTM)
(Delayed Data from NSDQ)
$3.99 USD
-0.01 (-0.25%)
Updated May 30, 2024 04:00 PM ET
After-Market: $3.98 -0.01 (-0.25%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Verastem, Inc. [VSTM]
Reports for Purchase
Showing records 221 - 240 ( 264 total )
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
3Q13 Results: Firmly Rooted in Execution Phase; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Defactinib Program Expands as Expected; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
2Q13 Results; Key Execution Phase in the Coming Months; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
R&D Day; Value Creation and Drug Differentiation
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Nice Incremental Data for One-Two Punch; Reiterate Buy.
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY.
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Meetings Highlight Strong ''6063 Positioning; Target Upped
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Mesothelioma Focus and Pending Pivotal Study for VS-6063
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
1Q13 Results; Going to FAK with Mesothelioma; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.